Mediclinic International plc Holding(s) in Company (4321O)
January 29 2019 - 8:30AM
UK Regulatory
TIDMMDC
RNS Number : 4321O
Mediclinic International plc
29 January 2019
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
29 January 2019
Notification of Major Interest in Mediclinic International plc
shares
1a. Identity of the issuer or the Mediclinic International plc
underlying issuer of existing shares
to which voting rights are attached:
--------------------------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
-----------------------
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights x
-----------------------
An acquisition or disposal of financial instruments
-----------------------
An event changing the breakdown of voting rights
-----------------------
Other (please specify):
-----------------------
3. Details of person subject to the notification obligation
Name Mpilo Investment Holdings 2 (RF)
(Pty) Ltd
City and country of registered office Stellenbosch, South Africa
(if applicable)
4. Full name of shareholder(s) (if different from 3.)
Name N/A
--------------------------------------------------------------
City and country of registered office
(if applicable)
--------------------------------------------------------------
5. Date on which the threshold was 29/01/2019
crossed or reached:
--------------------------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 29/01/2019
--------------------------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number of voting
rights attached through financial in % (8.A rights of issuer
to shares (total instruments + 8.B)
of 8. A) (total of 8.B
1 + 8.B 2)
----------------------- ------------------- ---------------- -----------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 0% 0% 737 243 810
----------------------- ------------------- ---------------- -----------------------
Position of
previous notification
(if
applicable) 3.33% 3.33%
----------------------- ------------------- ---------------- -----------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
---------------------
0 0%
-------------------- --------------------- ---------------------------------- ---------------------
SUBTOTAL 8. A 0 0%
------------------------------------------- ---------------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion Period rights that may rights
instrument be acquired if
the instrument
is
exercised/converted.
-------------------- --------------------- ---------------------------------- ---------------------
SUBTOTAL 8. B 1 NIL NIL
--------------------- ---------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date Conversion cash voting rights rights
instrument Period settlement
--------------------- --------------------- --------------- -----------------
SUBTOTAL 8.B.2 NIL NIL
--------------- -----------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer
Full chain of controlled undertakings through which the voting rights X
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (please add additional
rows as necessary)
Name % of voting % of voting rights Total of both if
rights if through financial it equals or is
it equals instruments if higher than the
or is higher it equals or notifiable threshold
than the notifiable is higher than
threshold the notifiable
threshold
------------------------ -------------------- ----------------------
Phodiso Holdings Limited
------------------------ -------------------- ----------------------
Mpilo Investment Holdings
2 (RF) (Pty) Ltd 0% 0%
------------------------ -------------------- ----------------------
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
--------------------------------------------
The number and % of voting rights held N/A
--------------------------------------------
The date until which the voting rights N/A
will be held
--------------------------------------------
11. Additional information
Mpilo Investment Holdings 2 RF (Pty) Ltd has been one of Mediclinic's
empowerment partners since 2005 and the contractual arrangements of their
investment expired on 31 December 2018.
Place of completion Stellenbosch, South Africa
-------------------------------------------------------------------------
Date of completion 29/01/2019
-------------------------------------------------------------------------
Mediclinic has a primary listing on the Main Market of the LSE
in the United Kingdom, with secondary listings on the JSE in South
Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International
plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank
Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
HOLUKAORKRAAUAR
(END) Dow Jones Newswires
January 29, 2019 08:30 ET (13:30 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2023 to Apr 2024
